Aurobindo Pharma Ltd.

With a decisive breakthrough to Rs 1497.55 on 7 May 2026, Aurobindo Pharma Ltd. has reached a fresh 52-week high, propelled by a confluence of bullish technical indicators and sustained price momentum that outpaces the broader market’s modest gains.

Surging to a fresh 52-week high of Rs 1465 on 6 May 2026, Aurobindo Pharma Ltd. has demonstrated robust price momentum, outpacing its sector and the broader market with a 21.13% gain over the past year against the Sensex’s decline of 4.18%.

Aurobindo Pharma Ltd. is rated Buy by MarketsMOJO, with this rating last updated on 24 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 April 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

With a decisive break above Rs 1429.8 on 23 Apr 2026, Aurobindo Pharma Ltd. has reached a new 52-week high, extending its recent momentum amid a mixed broader market backdrop. The stock’s steady climb over the past three days, delivering a 4.2% gain, underscores a robust technical setup that has propelled it beyond key resistance levels.

With a decisive surge to Rs 1415 on 22 Apr 2026, Aurobindo Pharma Ltd. has reached a fresh 52-week high, marking a significant milestone in its price momentum. This advance comes amid a backdrop of strong technical signals and sustained upward movement across multiple timeframes, setting the stage for a compelling momentum narrative.

Aurobindo Pharma Ltd. has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and potential directional bets. The pharmaceutical giant’s stock hit a new 52-week high of Rs 1,401.1 on 21 Apr 2026, outperforming its sector and reflecting renewed investor confidence amid robust volume and price action.

Aurobindo Pharma Ltd. has witnessed a significant surge in open interest (OI) in its derivatives segment, reflecting a notable shift in market sentiment and positioning. The stock hit a fresh 52-week high of Rs 1,401.1 on 21 Apr 2026, outperforming its sector and signalling renewed investor confidence amid evolving volume and price dynamics.

Surging to an intraday peak of Rs 1401 on 21 Apr 2026, Aurobindo Pharma Ltd. has marked a significant milestone by reaching a fresh 52-week high. This advance comes amid a backdrop of sustained technical momentum and a broader market rally, underscoring the stock’s robust price action over the past year.

Aurobindo Pharma Ltd. has witnessed a significant surge in open interest (OI) in its derivatives segment, with a 20.55% increase to 61,859 contracts from the previous 51,316. This sharp rise, coupled with robust volume and price action near its 52-week high, suggests a strengthening bullish sentiment among market participants, reflecting a potential directional shift in the mid-cap pharmaceutical stock.

Aurobindo Pharma Ltd. has witnessed a notable 13.3% increase in open interest in its derivatives segment, signalling heightened market activity and potential directional bets. The surge accompanies a steady price recovery and robust technical indicators, positioning the mid-cap pharmaceutical stock favourably within its sector.

Aurobindo Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market activity and evolving investor positioning. Despite a modest price decline and underperformance relative to its sector, the stock’s rising OI and volume patterns suggest nuanced directional bets by traders ahead of potential market catalysts.

Aurobindo Pharma Ltd. has witnessed a significant 31.5% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this, the stock has underperformed its sector and declined modestly over the past two sessions, raising questions about the directional bets underpinning this spike in open interest.

Aurobindo Pharma Ltd. has witnessed a significant surge in open interest in its derivatives segment, with a 31.23% increase signalling heightened market activity and shifting investor positioning. Despite this, the stock has underperformed its sector and declined modestly over the past two sessions, raising questions about the underlying directional bets and market sentiment.

With a fresh 52-week high of Rs 1396.6 reached today, Aurobindo Pharma Ltd. has demonstrated notable price momentum, outperforming the broader market and its sector peers over the past year. This milestone caps a steady rally from its 52-week low of Rs 1017, reflecting a sustained uptrend supported by multiple technical indicators aligning favourably.

Aurobindo Pharma Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 24 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 April 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

With a decisive move to Rs 1394.1 on 17 Apr 2026, Aurobindo Pharma Ltd. has reached a fresh 52-week high, propelled by a confluence of bullish technical indicators and sustained price momentum that outpaces its sector and the broader market.

Surpassing its previous peak, Aurobindo Pharma Ltd. touched a new 52-week high of Rs 1392 on 16 Apr 2026, marking a significant milestone in its price momentum. This advance comes amid a backdrop of broad technical alignment and steady market conditions, underscoring the stock's sustained upward trajectory over the past year.

With a decisive surge to Rs 1370.2 on 15 Apr 2026, Aurobindo Pharma Ltd. has marked a fresh 52-week high, extending its impressive 20.75% return over the past year and outpacing the Sensex’s modest 1.59% gain. This milestone reflects a strong technical momentum that has propelled the stock well above all key moving averages, signalling robust underlying price strength.